Niagen Bioscience, Inc. (NASDAQ:NAGE) Given Average Rating of “Moderate Buy” by Analysts

Niagen Bioscience, Inc. (NASDAQ:NAGE) has been assigned an average rating of “Moderate Buy” from the five brokerages that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $14.2750.

NAGE has been the topic of a number of recent analyst reports. Canaccord Genuity Group lowered their price objective on Niagen Bioscience from $16.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Weiss Ratings restated a “hold (c)” rating on shares of Niagen Bioscience in a research report on Thursday, January 22nd.

Insider Transactions at Niagen Bioscience

In other news, CFO Ozan Pamir acquired 4,465 shares of the business’s stock in a transaction dated Friday, November 14th. The stock was purchased at an average cost of $6.81 per share, for a total transaction of $30,406.65. Following the acquisition, the chief financial officer owned 7,372 shares of the company’s stock, valued at $50,203.32. This trade represents a 153.59% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 9.39% of the stock is currently owned by company insiders.

Institutional Trading of Niagen Bioscience

Several hedge funds and other institutional investors have recently bought and sold shares of NAGE. Precision Wealth Strategies LLC bought a new position in shares of Niagen Bioscience in the third quarter worth approximately $1,527,000. BSW Wealth Partners purchased a new stake in shares of Niagen Bioscience during the third quarter worth about $793,000. Hussman Strategic Advisors Inc. bought a new stake in shares of Niagen Bioscience in the third quarter worth about $980,000. Silverberg Bernstein Capital Management LLC bought a new stake in shares of Niagen Bioscience in the third quarter worth about $1,169,000. Finally, State of Alaska Department of Revenue purchased a new position in Niagen Bioscience during the 3rd quarter valued at about $44,000. Hedge funds and other institutional investors own 15.41% of the company’s stock.

Niagen Bioscience Stock Down 0.7%

Shares of NAGE opened at $5.99 on Friday. Niagen Bioscience has a twelve month low of $5.25 and a twelve month high of $14.69. The stock has a market cap of $478.06 million, a PE ratio of 24.96 and a beta of 2.35. The business’s 50-day moving average price is $6.48 and its 200-day moving average price is $7.98.

Niagen Bioscience (NASDAQ:NAGE) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.02 by $0.03. Niagen Bioscience had a net margin of 16.38% and a return on equity of 24.13%. The company had revenue of $33.99 million during the quarter, compared to analysts’ expectations of $31.30 million.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.